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Abstract-In this article we introduce the notion of entrenchment to conceptualize the processes in which 
new technological options, through the interactions between a variety of actors, become viable and 
established practices in society, both satisfying and modifying needs and interests. The notion of 
entrenchment we use as a framework for an analysis of developments and debates in the field of cystic 
fibrosis testing and screening in Denmark. On the one hand, it appears that the development and 
introduction of cystic fibrosis (CF) screening to some extent is predetermined both by existing networks 
of human genome researchers, clinical geneticists, patients (organizations), funding organizations, and 
regulatory agencies, and by existing practices like that of prenatal diagnosis. On the other hand, in 
Denmark, the content and future of CF screening is shaped in ongoing processes or articulation of demand 
for screening and of its cultural and political acceptability, processes which also involve political 
decision-making and which (may) result in new networks and regimes. Yet, what appears to be an inherent 
and undecided part of the process of entrenchment of CF screening in Denmark, is how to allocate 
responsibilities and authority to decide what is acceptable and what not. 
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INTRODUCTION 
In a comment on the ethical and social consequences 
of the international genome mapping effort, Sydney 
Brenner, a leading British molecular biologist 
and ardent promoter of the human genome project, 
argues that we should separate the discussion about 
the project into two parts: one concerning the 
acquisition of the knowledge, the other its appli- 
cation. He then goes on to explain that the knowledge 
itself can be only neutral and that “everything else 
that will stem from the knowledge, good or bad, 
will take place outside the laboratory in the social 
realm”. So, it is society that should properly exercise 
the choices on the application of scientific knowledge. 
In advancing this view, Brenner opposes what he 
calls the “Pandora’s box argument” of those who 
think we should stop the research before it is let 
loose on the world because opening the box will 
initiate an inevitable causal chain leading to future 
disaster [ 11. 
*This rhetoric we do not only find among scientists, but also 
in political debates about human genome research and 
its implications. For example, when the European Com- 
mission proposed to add to the EC programme of 
Human Genome Analysis a special programme to study 
and evaluate the implications of human genome re- 
search, the Commission neatly distinguished science as a 
quest for pure knowledge from society as a body which 
should carefully consider the applications of this knowl- 
edge [6]. 
Brenner is not the only scientist involved in the 
human genome project who, in response to fears 
about inevitable ethical and social implications, trust- 
fully refers to society. Thus, in discussions of the 
implications of the project, Brenner, Gilbert and 
Watson all emphasize that it is society that should 
properly exercise choices, deal with the problems in 
a democratic way, and learn to use information only 
in beneficial ways [2-51. A striking feature of this 
rhetoric is that both science and society appear as 
highly black-boxed and clearly separated entities. On 
the one hand we have ‘science’ or the ‘laboratory’ 
producing knowledge and technologies, on the other 
hand we have ‘society’ deciding upon, or setting limits 
to, the uses of new knowledge and technologies.* 
Thus, what is suggested in this rhetoric is a very 
simple model of the relationship between science and 
society (Fig. 1). In this article, we suggest another 
more complex model of this relationship (Fig. 2). 
Based on a more thoroughgoing sociological analysis 
of science and technology, the model implies that the 
development and introduction of new technologies in 
society take shape in complex interactions in which, 
on the one hand, many different actors are shaping 
technology and, on the other hand, technology be- 
comes a means for actors to (re)shape society. Thus, 
of the two notions-‘science’ as Pandora’s box simply 
forcing its products on society, or ‘society’ neatly 
deciding about whether and how these products 
should be used-neither does apply. Both these 
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I-ig. I. A (too) simple model of the relationship between 
science and society. 
notions are only taking to the extreme some simplified 
version of a complex process of socio-technical 
change. 
To substantiate our model we USC the concept of 
entrenchment as a notion referring to the processes in 
which new technological options, through the intcr- 
actions between a variety of actors. become viable and 
established practices in society, both satisfying and 
modifying needs and interests. In recent sociology and 
economics of technology we find attempts to create a 
comprehensive analysis of processes of societal en- 
trenchment of technology [7]. Such attempts may help 
us to understand the intricacies of what is often so 
misleadingly called the ‘diffusion’ of technology 
through society*. In this article we will use the notion 
of entrenchment as a framework for an analysis of 
developments and debates in the field of cystic fibrosis 
(CF) testing and screening in Denmark. On the one 
hand, we will show that the development and intro- 
duction of CF testing to some extent is predetermined 
in our society both by existing networks of human 
gcnome researchers, clinical geneticists, patients (or- 
ganizations), funding organizations, and regulatory 
agencies, and by existing practices like that of prenatal 
diagnosis. On the other hand, we will show how the 
content and future of CF testing is shaped in ongoing 
processes of articulation in which the demand for and 
acceptability of particular options for screening are 
negotiated among a variety of actors. These processes 
also involve political decision-making and may result 
in new networks and regimes. In other words, the 
history of CF testing is neither simply a question of 
‘society’ deciding about the application of a test, nor 
simply a question of ‘technology’ forcing itself upon 
society. Only in the sense that existing socio-technical 
networks and regimes promote the entrenchment of a 
particular technology we may say indeed that technol- 
ogy forces itself upon society, but it is also the other 
way around. Just because technology depends for its 
entrenchment on elaboration of new networks and 
*For a critique of the model of diffusion see [8]. Some 
authors who use the notion of diffusion come very close 
however to an analysis which includes all the elements of 
what we would call entrenchment. See for example 191. 
Sclrntlsts ~ Regulatory 
Fig. 2. A less simple model of the relationships between 
(biomedical) sctence and society. 
regimes it depends for its success on negotiations and 
decisions in society. 
THE SOCIOLOGV OF ENTRENCHMENT 
The concept of entrenchment of technology is used 
to emphasize that there is more to the introduction of 
new technologies than putting a new product into ‘the’ 
market and having it adopted by users (or not, as the 
cast may bc). Societal entrenchment is a process 
including further technological development, articula- 
tion of demand for specific applications of a particular 
technology, and. increasingly, articulation of cultural 
and political acceptability. In the domain of human 
genetics. we have seen in the past decade a rapid 
emergence of new technological options to diagnose 
genetic disorders. coupled with increasing demand for 
specific applications. Articulation of such demands is 
not automatic. however. It requires activities like 
arrangements to reimburse diagnostic tests, possibili- 
ties of counselling. education, training of doctors and 
social workers. Thus, application of a new technology 
requires the creation of an environment in which such 
applications can actually be realized. in which tech- 
nology can be ‘entrenched’. 
In addition to articulation of demand, the introduc- 
tion of new technologies in society more and more 
also needs efforts to insure its cultural and political 
acceptability. especially in view of potential adverse 
implications for society. This point is obvious in the 
case of the new human genome technologies (or 
indeed new genetic technologies in general). The de- 
velopment and societal entrenchment of these tech- 
nologics meets with questions, concern and resistance 
and leads to reflection and debate involving various 
parties: researchers. clinical gcncticists, patients and 
their organizations. ethicists. feminist groups, govern- 
ment and parliamentary committees. etc. Issues of 
cultural and political acceptability of human genome 
technologies, especially their use in testing and screen- 
ing programmes (including CF screening), have been 
articulated in a great number of studies [IO-161, and 
have become a special matter of concern in official 
programmes for evaluation of ethical, social 
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and legal issues as part of the international human 
genome initiative*. 
Our analysis of entrenchment focusses on the way 
in which, in the interactions between actors like 
innovators, users, funding bodies, service organiz- 
ations and regulatory agencies, a mutual attuning and 
alignment emerges between the development of new 
technological options, articulation of demand, and 
articulation of acceptability. Thus, in our discussion 
of the question of societal entrenchment of CF testing 
and screening, the following issues are of central 
importance. 
Attunement qf’ technical options and demand 
Entrenchment of technology in society will result 
in, and be the outcome of, a mutual attuning of 
technical options and demand. This attunement in- 
volves on the one hand processes of technical specifi- 
cation, in which the content and meaning of a 
particular technical option (like a genetic test) be- 
comes further specified in practice, and on the other 
hand processes of articulation of demand, in which 
producers as well as consumers further specify needs 
and demands in relation to available technical op- 
tions [ 17, 181. Technical specification and articulation 
of demand are the explicit aims of many of the pilot 
projects on CF screening that are going on in the US 
and elsewhere. Technical specification relates to the 
kind and number of mutations to be included in the 
test and to the procedures followed in conducting the 
test (to whom and in what way will the test be 
offered?). At the same time demand is articulated in 
these projects, identifying “factors that affect a 
couple’s decision whether or not to be screened”, 
determining “predictors of consent”, determining 
“what proportion (of women of reproductive age) 
desires it”, etc. [l4, p. 161. 
Attunement of technical options and acceptability 
Entrenchment of technologies also needs activities 
directed to overcoming, or adapting to, concern and 
resistance. Here we can distinguish processes of artic- 
ulation of cultural and political acceptability, in 
which potential impacts and issues of acceptability 
are defined, from the specification of technical and 
social practices as a means to cope with these impacts 
and issues. Articulation of cultural and political 
acceptability is taking place in professional and pub- 
lic debates or controversies, but is also shaped by 
evolving practices of regulation and assessment, in- 
cluding official impact studies like the recently pub- 
lished OTA report on CF carrier screening. Current 
*For the American Ethical, Legal, and Social Issues pro- 
gramme see the first five year plan of the US human 
genome project, US Department of Health and Human 
Services and US Department of Energy, 1990. For the 
European programme see the report of the Working 
Group on the Ethical, Social and Legal Aspects of 
Human Genome Analysis, 1991. 
pilot projects on cystic fibrosis screening also can be 
seen as a means to articulate acceptability and to 
specify practices in accordance with notions of ac- 
ceptability. These projects include studies of ‘psycho- 
logical impact following testing’ and ‘responses to 
implications of the test results’, and seek to specify 
procedures for screening in response to notions of 
acceptability [l4, p. 161. An interesting example of 
such attempts at specification of technical procedures 
is the introduction, in a British pilot project, of 
‘couples screening’ to avoid the implications of know- 
ing one’s individual carrier status [ 14, p. 151. Issues of 
cultural and political acceptability may also lead to 
attempts at regulation through institutional or legal 
means. In relation to genetic screening practices 
institutional or legal means are used or advocated for 
example to ensure quality control or to preclude 
discrimination. 
The role of existing ‘niches’ and ‘regimes’ 
New technological options cannot survive in so- 
ciety without being entrenched in networks of pro- 
ducers, users and various services. Thus, the initial 
steps taken in the development of some new techno- 
logical option will often be strongly determined by 
existing networks in society which constitute ‘niches’ 
offering advantageous opportunities for particular 
applications. More in general we may speak of 
‘regimes’, that is, mutually adapted and coordinated 
technological, organizational and societal practices 
which are the result of earlier processes of attunement 
between technological options, demand and accept- 
ability. The existing regime of prenatal diagnosis 
constitutes for example an important niche in our 
society for the entrenchment of a rapidly increasing 
number of new genetic tests based on DNA-diagno- 
sis. This is clearly illustrated by the design of the 
earlier mentioned pilot projects on CF screening. 
Many of these projects have started with women 
enrolled in prenatal diagnosis as their target popu- 
lation. Thus it is reported in the OTA study on CF 
carrier screening that “initially, routine CF carrier 
screening will likely occur in the reproductive con- 
text” since “the prenatal population has been the 
traditional entry point into genetic services for many 
people” [14, p. 141. In this way, existing networks and 
regimes do not only shape the content and meaning 
of new technological options, but also predetermine 
the entrenchment of these options in society. That is, 
as far as, in the context of these regimes, questions of 
demand and acceptability can be taken for granted by 
the various parties in the network, such regimes will 
strongly facilitate the entrenchment of new technol- 
ogies in society. Revealing in this respect is the 
conclusion of the earlier mentioned OTA study that 
“without offering judgment on its appropriateness or 
inappropriateness, OTA finds that the matter of CF 
carrier screening in the United States is one of when, 
not if” [l4, p. 161. 
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In processes of entrenchment of technology issues 
of demand and acceptability often will be inextricably 
related as is clearly illustrated by the questions exam- 
incd in studies and pilot projects on CF screening. 
Yet. there are good reasons to distinguish processes 
of articulation of demand from processes of articula- 
tion of cultural and political acceptability. Although 
a variety of actors is involved in either process, there 
is general agreement about the authority of the 
‘autonomous’ consumer or patient in deciding about 
questions of demand. The picture is far less clear 
however in dealing with issues of cultural and politi- 
cal acceptability. Here, the question who has the right 
to speak authoritively about these issues is often an 
undecided and controversial issue. Thus. articulation 
of cultural and political acceptability is often also a 
question of articulating who has the right to decide 
in which terms about what*. In the field of genetic 
diagnosis, governments in general will guarantee the 
availability of particular genetic services in the con- 
text of the national health system and, in doing so. 
may also introduce regulation which binds the avail- 
ability of thcsc services to certain conditions, cs- 
pecially in regard to costs. Governments usually will 
also bc involved in quality control. for example in 
regard to reliability of diagnostic genetic tests. 
Finally. the issue of ethical and social implications 
may be a ground for regulation and government 
interfcrcncc. This form of regulation we find embod- 
ied for example in the activities of national and local 
ethical committees. The question whether. and in 
what form. government interference is desirable and 
legitimate in regard to ethical and social implications 
of genetic technologies is far from decided howevert. 
In the next part of this article we will use the 
analysis of societal entrenchment of technology as a 
framework for discussing the entrenchment of CF 
testing and screening in Denmark. As the following 
history will make clear. we arc moving here along a 
path which started in 1987 with the straightforward 
and generally accepted introduction of CF-testing for 
*In the OTA report on CF screenmg the question “who 
serves as gatekeepers of a new technology” is mentioned 
as one of the controversial issues surrounding the grow- 
ing practice of CF screening (p. 18). From a recent 
overview of the process of bioethical decision-making in 
the United States it becomes clear that there is a variety 
of actors involved and that one question to be resolved 
in the process is ‘who will decide’. See [19]. 
tlllustrative m this respect is the discussion about the role 
of Congress in the OTA report on CF screening. See also 
Ruth Schwartz Cowan‘s discussion of genetic technol- 
ogy and reproductive choice. in which she strongly 
opposes government interference in reproductive de- 
cisions for reasons of personal freedom and autonomy, 
concluding that “if nothing else. the history of the 
twentieth century ought to have taught us that individ- 
uals can sometimes behave badly, but they can never 
behave as badly, or as destructively. as governments” 
(20. p. 163) 
high-risk individuals in a medical context, and then 
proceeded, after the localization of the CF-gene in 
1989. with the establishment of a pilot screening 
programme which has become more and more con- 
troversial however. In regard to CF testing in the 
medical context. everything was ‘in place’, so to 
speak. Established networks and regimes gave actors 
a certain space and autonomy, questions of demand 
and acceptability had been negotiated and could be 
taken for granted. Yet, in the case of population 
screening, a situation has emerged in which questions 
of demand and acceptability cannot be taken for 
granted any longer and issues as well as actors have 
to be ‘put into place’ yet. 
THE ENTRENCHMENT OF CF SCREENING IN DENMARK 
For at least three reasons, Denmark is an intcrest- 
ing country for a study of the entrenchment of the 
genetic diagnostic test for CF which became available 
after the cloning of the most common mutation of the 
CF gene (Delta 508) in 1989. First. Denmark is 
probably the country in Europe with the highest 
prevalence of the Delta 508 mutation (88%) and also 
has a rather high frequency of CF in the population 
(I : 4760). Second, Danish biologists were in the front 
line when the CF gene was localized on chromosome 
7 in 1985 [2l, 221 and lastlyPperhaps influenced by 
these 2 previous factors-Danish CF experts have 
considered Denmark the ideal country to take the 
lead in CF screening: immediately after the cloning of 
the gene, in late 1989, a pilot programme was in- 
itiated by the section of clinical genetics at the 
University Hospital of Copenhagen to screen 7000 
pregnant women in greater Copenhagen in order to 
“illuminate the technical, informational. psychologi- 
cal and ethical problems of a CF carrier screening” 
[23]. This step was facilitated by the existence of a 
publicly financed practice of prenatal care in Den- 
mark. including broadly accepted prenatal diagnosis 
of a large section of the pregnant population. Since 
>99% of the pregnant population attcnt prenatal 
care and give birth in registered hospital clinics, total 
screening of virtually all pregnant women as well as 
centralized registration of their genetic data is poss- 
ible. Thus, in Denmark, the initial steps in a process 
of entrenchment of CF screening took place in the 
reproductive context thanks to the existence of an 
elaborate regime of prenatal care in which new forms 
of genetic testing can be easily implemented. As we 
will see, the introduction of CF screening in this 
regime of prenatal care was further promoted by the 
existence of a strong and centralized CF network 
involving genetic researchers. clinicians and a CF 
patient organization. 
In the following we will first discuss the features of 
this Danish CF network and show how in this 
network a practice was established of prenatal testing 
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of high risk individuals. Then, we will show how the 
content and fate of CF testing in Denmark is being 
shaped in an ongoing process of articulation of 
demand and acceptability and a process of nego- 
tiation between a variety of actors making up an 
increasingly complex network. A network involving 
not only researchers, clinicians and a patient organiz- 
ation. but also different kinds of ethical evaluatory 
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The CF network in Denmark 
The leading CF unit in Denmark, the centre for 
research and treatment of Cystic Fibrosis, is situated 
at the University Hospital of Copenhagen. Here a 
small group of biochemists, paediatricians and lung 
specialists have created a reknowned unit for CF 
research as well as the nation’s most treatment- 
efficient centre for the diagnosis and treatment of 
CF. In 1990 the centre was converted into a national 
centralized unit by the National Board of Health 
after documentation had been provided that treat- 
ment efficiency was significantly lower in smaller 
regional centres than in the medically and technically 
more advanced Copenhagen unit [24]. The central- 
ization process, which was thus supported by the 
national health authorities, was important for the 
process of creating a strong and coherent CF net- 
work, commanding the majority of the resources 
attributed to CF research and treatment in Den- 
mark. 
Fig. 3. The Danish CF network before 1989. 
efforts of the three groups-the CF unit, the section 
of clinical genetics, and the CF association, could in 
several respects be said to form a seamless web 
(Fig. 3). 
Prenatal testing of high risk individuals 
With the advent of the first findings of markers of 
the CF gene in 1987, the unified network, including 
enthusiastic CF parents wanting another but un- 
affected child, supported the introduction of prenatal 
diagnosis in people with a family history of CF. 
Since the advent of prenatal diagnosis for CF > 90% 
of those offered the test (riskpersons consulting the 
CF unit) have chosen prenatal diagnosis for CF and 
virtually all of those with an affected fetus have 
aborted [25]. 
The national CF unit is working in close co- The development and introduction of the first CF 
operation with the section of clinical genetics at the test on a genetic level has taken place in a medical 
University Hospital of Copenhagen which has devel- context of research and care for CF patients and 
oped fruitful contacts to international research their relatives. The fact that research has required the 
centres, including genetic research associations such cooperation of patients and their families, and the 
as the CF genetic analysis consortium. Here the fact that patients have obtained important benefits 
molecular-biological findings of CF genetics from 80 from research in the form of information, prenatal 
labs all over the world are pooled and coordinated diagnosis and a sense of being partners at the front- 
for everyone to use freely, a structure that has been line of science, has contributed to the convergence of 
conducive to the development of CF genetics. The the CF network. Within the network, the introduc- 
CF unit also works very closely together with the tion of CF testing among high risk individuals has 
Danish association for the struggle against CF- been a rather straightforward matter, and consistent 
officially a patient association but actually rather a with the dominant practice in the Danish health 
national organization of medical doctors, patients service system that people with an increased risk of a 
and patients relatives characterized by great expec- hereditary disease have automatic and free access to 
tations to medical and genetic research. The CF prenatal diagnosis. There has been no public discus- 
association is unique among patient organizations in sion about the use of the CF test in this high risk 
Denmark for its energetic lobbying for easier access group, since prenatal diagnosis and abortion enjoy a 
to prenatal diagnosis to avoid the birth of handi- high degree of public acceptability. In other words, 
capped children, for its international orientation and when the option for CF testing in high risk individ- 
its efficient fundraising practices. The funds raised by uals came within reach, questions of demand and 
the association finance several research projects at acceptability were taken for granted. At this point 
the CF unit in the University Hospital, including a in the history of entrenchment of CF testing in 
study of the reproductive function of CF patients, Denmark, the development and introduction of a CF 
microbiological studies of lung infections and most test in prenatal diagnosis as provided to individuals 
recently a study of public acceptability of CF screen- with a family history of the disease was indeed 
ing. In almost all outreaching activities do the CF predetermined by the existence of a CF network of 
unit and the CF association act in harmony, often genetic researchers, clinicians and patients and an 
countersigning each others actions. The combined existing regime guiding access to prenatal diagnosis. 
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From testing to screening 
As mentioned above, the section for clinical gen- 
etics at the University Hospital in Copenhagen 
launched a pre-planned carrier screening pilot study 
of pregnant women in greater Copenhagen as soon as 
the CF gene was cloned in late 1989. The pilot project 
was exclusively funded by the University Hospital 
after failed attempts to obtain external funding. The 
screening programme offered a CF test to all preg- 
nant women consulting the hospital in the period 
1990-1992: if a woman was found to be a carrier, her 
partner was offered the test: if both were carriers. they 
were offered prenatal diagnosis. Almost 7000 women 
were screened; I72 hetorozygotes were found; eventu- 
ally one fetus was found to be affected and was 
subsequently aborted [25]. 
Although CF testing of high risk individuals might 
be considered quite a different thing than a general 
screening of the population, questions of demand for 
and acceptability of CF screening have been articu- 
lated from within the CF network as quite a straight- 
forward matter and completely comparable to the 
current practice of testing of high risk individuals. In 
the eyes of the leading geneticist at the section for 
clinical genetics there is a direct link between testing 
in high risk families and screening of low risk popu- 
lations. “Almost all families with a CF child ask for 
prenatal diagnosis if they want more children and 
choose to have an abortion if the fetus appears to 
have CF. On this background I find it natural that 
you do not want to have your first child with CF if 
that can be avoided”. And the head of the national 
CF unit adds “The moment the gene was found I 
said: Now we must start carrier screening programme 
as soon as possible. I didn’t really discuss it with 
anybody because our experience with prenatal diag- 
nosis in families with a CF child was so good. So I 
found that the rest of the population should be 
offered a carrier test so that they could avoid having 
a child with CF” [ 16. p. 241. Thus. the demand for CF 
screening in Denmark was articulated first of all by 
those highly involved in the existing CF network, 
whereby the current practice of CF testing of high 
risk individuals served as a model for the design and 
justification of the intended pilot project 
Within the CF network only one important contro- 
versy seems to have arisen in the context of the 
screening programme. i.e. concerning the relative 
importance of a semistructured interview survey 
among the participants. The CF patient association 
*The limited scope of the present study will probably make 
it difficult to redeem the purposes of the screening 
programme which were to illuminate “the psychological 
and ethical issues related to carrier screening”. 
tEventually the CF association has managed to obtain 
financing of a retrospective interview study covering all 
the groups included in the pilot programme. This study 
will show whether non-risk families share the view of 
CF-families on CF screening. 
and its managing director had taken the initiative to 
include such a survey to determine public acceptabil- 
ity in the screening project, but for financial and other 
reasons the clinical geneticists did not manage to 
integrate this survey into the overall plans. The study 
proposed and eventually financed by the patient 
association was put off and instead only a very 
limited psycho-social study was included in the pro- 
gramme. The population of this study does not 
include all those screened, as planned in the original 
study, but only the detected carriers as well as a 
similarly sized group of women screened but not 
found to be carriers*. The failure to do the overall 
study led to major frustration in the CF association. 
though the fact that a study managed to be decided 
upon at all was considered a positive turn of events. 
Furthermore promises were made to try to make a 
follow-up study of the people interviewed, and this as 
well as the good will of the association has con- 
tributed to the solution of the controversy [26]t. 
Though the CF patient association had been frus- 
trated by their fruitless attempts to obtain a comprc- 
hensive survey of user acceptability, there is a close 
congruence of view between the association and the 
medical CF community regarding the desirability of 
a screening programme. According to the associ- 
ation: “This is something we have been hoping for for 
many years”. Access to prenatal diagnosis is ncccss- 
ary it is claimed if “families shall have the possibility 
to decide for themselves after counselling if they want 
to give birth to a CF child or not”. And. as the 
association further states, it is “very grateful that also 
pregnant women outside the already known risk 
groups will now be able to benefit from this otfer” 
[l6, p. 271. But how can the CF association with a 
knowledge limited to the cxpericnce of affected 
families evaluate the acceptability of screening to the 
population as such? In an interview the managcr-gen- 
era1 of the CF association admits to this difficulty: 
“As an association representing risk families WC are 
not able to decide whether a general screening should 
be introduced. This is the opinion of opponents in 
our organisation as well as of supporters In our 
organisation it is crucial that the test is voluntary. 
You must decide for yourself whether you want the 
test” [Ih, p. 271. 
Thus, in conjunction with the medical CF commu- 
nity, the CF patient association has been active in 
articulating both demand and acceptability of CF 
screening in Denmark. Ths ability to decide for 
yourself appears in this process of articulation as a 
basic value, explicitly or implicitly implied in the 
statements of those involved in the CF network. 
However, as is demonstrated by the controversy 
about the CF association’s proposal to study public 
acceptability of CF screening, questions of demand 
and acceptability are not conceived of in identical 
terms by the section of clincal genetics on the one 
hand and the CF association on the other. The 
association airs doubt about the direct link between 
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testing and screening and needs confirmation by a 
study of acceptability before the process should con- 
tinue. Although, in the network, the tension about 
this issue was resolved, this is not the end of the 
study. With the advent of the screening programme 
new actors appeared on the stage, and issues of 
acceptability became part of negotiations in an in- 
creasingly complex network. 
Scient$c and ethical evaluation 
Although, in Denmark, the National Board of 
Health is the supreme authority in health matters, it 
has not been necessary to officially consult it, neither 
has it played any role in the planning or decision- 
making processes related to the CF screening pro- 
gramme. The Board has however for a number of 
years been warning against the initiation of screening 
and other preventive programmes without proper 
documented health or economic benefits. This policy 
of ‘rational health care’, in which a utilitarian cost- 
benefit approach is employed to many new medical 
technologies, has only had little success, because of 
the decentralized organizational structure of the 
health services in Denmark. Initiation of a screening 
programme as this one is completely within the 
domain of the leading medical doctor of the clinical 
department, who has so-called ‘methodological free- 
dom’ of research and treatment of his patients. The 
pilot programme is a research programme, and 
thus within the bounds of methodological freedom. 
Where innovative research ends and routine practice 
begins is however an open-ended question, which 
leaves room for de facto entrenchment of new tech- 
nologies and practices without any formal official 
decision. 
What every biomedical research project needs how- 
ever, according to Danish practice, is a ‘start-permit’ 
from the scientific ethical committee system, orig- 
inally a professional control system but given legal 
status by law in 1992. The necessity of obtaining a 
permission from the regional Scientific Ethical com- 
mittee was relatively easily fulfilled (and probably 
made easier since the application included a letter of 
recommendation from the CF association). The com- 
mittee only required a minor change in the letter to 
the participating individuals before the permit was 
issued, plus reassurance that the waiting period be- 
tween testing and disclosure of result was minimized. 
The ethical problems related to introducing, for 
the first time in Danish medical history, a prenatal 
screening programme to detect carriers rather than 
sick or potentially sick people were mentioned. They 
were however not addressed directly, but were 
rephrased as cost-benefit issues concerning the 
*Although the Scientific Ethical Committee, like the Na- 
tional Board of Health, can be seen as a supporter of a 
utilitarian viewpoint, their evaluation of costs and ben- 
efits did not include the overall health economical inter- 
ests which predominate in the Board of Health. 
proper weighing of the cost of (un)necessary worries 
among the tested individuals and more provoked 
abortions vs the benefit of a almost total eradication 
of CF. The basic criterion here was the degree of 
medical seriousness of CF. “In the face of such 
serious diseases it was found justified to perform 
a comprehensive screening of the total population”. 
Only in the case of serious disease though and it 
was added, “in the interest of the preservation of 
biological diversity, one had to accept that individ- 
uals might have to live with a reduction in the 
quality of life, when these reductions were not 
seriously debilitating” [27, pp. 29-301. Thus, with this 
recognition of the acceptability of the CF screening 
project, the CF network had gained another associ- 
ate*. 
However, after publication of the project plans and 
a certain newspaper interest in the programme, a 
public controversy gradually developed, placing the 
issue of genetic screening programmes on the health 
political agenda. The major critic was the Danish 
Council of Ethics, an independent public body 
equally composed of laymen and scientists created by 
parliament in 1987 to monitor the developments in 
genetic and reproductive medicine. Attempts of this 
body to position itself in the genetic screening net- 
work would turn out to be a matter creating consider- 
able controversy. 
An ethical controrers_p 
Already in 1990 the Council of Ethics issued 
critical views of the CF programme [28, p. 541. Later 
in 1993, in a widely distributed pamphlet on genetic 
screening, the Council proposed two major changes 
for the implementation of future screening pro- 
grammes, proposals that were articulated in general 
terms, but with indirect reference to the CF project. 
One concerned the quality of the ethical evaluation of 
the necessary pilotprojects. The Council character- 
ized the scientific ethical evaluation, performed by the 
Scientific Ethical Committees as ‘insufficient’ and 
proposed an extra evaluation of “the general ethical 
issues related to genetic screening” performed by the 
Council [29, p. 651. Second, after the effectuation of 
such a pilot project the Council required to be 
consulted for another comment before the relevant 
authorities decide on the implementation of the pro- 
ject proper. Thus the Council of Ethics has made a 
bid to participate in the general genetic screening 
network, using CF as a wedge-just as the CF 
screening programme functions as a wedge for gen- 
etic screening as such-by claiming a position for 
itself as the relevant authority on “general ethical 
issues related to genetic screening” in opposition to 
what was defined as more specific scientific ethical 
issues, to be decided by the scientific ethical commit- 
tee system. What is at stake then in this discussion of 
acceptability is not only the question according to 
what ethical principles decisions should be made, but 
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also the question who should have the authority to 
decide*. 
At this point it is difficult to determine whether 
the viewpoints that separated the Council of Ethics 
from the Scientific Ethical Committees arc of 
principle or not. The Council repeatedly refers to a 
more deontological ethics and underlines the import- 
ance of respecting individual autonomy in the dc- 
cision-making process (in addition to the 
WHO guidelines), but whether this forms the 
content of the general ethical issues that the 
Council wants to have included in the evaluation of 
future screening programmes is not clear. If the 
authority claims of the Council of Ethics gain accep- 
tance, we may witness howcvcr a significant restruc- 
turing of the ethical-regulatory authority beginning 
in the area of genetic screening. A new regulatory 
regime may then cmergc in the field of human 
genetics, implying a further extension of the CF 
network (Fig. 4). 
The public, hrultil uutlwrities 
A new regulatory regime in the field of human 
genetics may not be the only hurdle to be taken in 
the process of entrenchment of CF screening in 
Denmark. In the foregoing we already mentioned 
the National Board of Health as the supreme 
authority in health matters. In this quality. the 
Board lays out guidelines on prenatal diagnosis 
that arc relatively binding for hospitals and prac- 
titioners. The present guidelines limits prenatal 
diagnosis to high risk individuals such as women 
above 35 years of age (at risk for Downs Syndrome) 
and women with a family history of hereditary 
disease. These guidelines are now under revision 
because of strong pressure to admit new diagnostic 
test methods and also to allow for a more individu- 
ally oriented admission practice (e.g. anxiety-indi- 
*In this case the question of authority became particularly 
controversial in the context of a recent debate in Den- 
mark on the legal status of the Scientific Ethical Con- 
mittees, in which it was proposed by the Council of 
Ethics that the Council and the CommIttees should 
become more or less parallel institutions. 
cation, individually determined risk status), though 
the Board of Health is extremely reluctant to aban- 
don its restrictive practice. The policy is twofold: 
only admission of high risk women. and no increase 
in costs. Thus. although the current regime of 
prenatal diagnosis in Denmark has been very helpful 
for the initial steps in the process of entrenchment of 
CF testing and screening. it may also become a 
barrier for the entrenchment of CF screening on ;I 
grand scale. CF screening may however find another 
way into the health cart system that evades this 
barrier. 
The Board of Health recently issued a publication 
on screening. out of a certain desperation that mot-c 
and more screening initiatives cropped up from the 
dcccntralizcd hospital system in Denmark without 
any documented effect [74]. Recent Danish medical 
history has provided several examples. IJltrasound 
WBS introduced locally as a prenatal diagnostic test 
and gradually spread without any documentation of 
its effect in routine screening of pregnant women and 
even after the Board of Health had issued a publi- 
cation documenting the lack of ctrect of routine 
screening it seemed extremely difficult to curb this 
diffusion process. Also AFP-maternal strum screen- 
ing for fetal defects has spread uncontrolled by 
national authority 111 Denmark. AFP-tests were in- 
itiatcd by a medical doctor in one Danish county and 
when the National Health authorities finally tried to 
intcrvenc. >40.000 Danish women (of a population 
of 5 mio) had been screcncd [JO]. Now a tremendous 
pressure exists to offer the AFP test to all women. 
Thus the mere initiative of a pilotproject may in itself 
create both a stepping stone for further screcning- 
projects and :I knowledge and demand that may 
hccome difficult to limit. What is interesting hcrc is 
the relationship between the issue of authority and 
the issue of acceptability. With the National Board 
of Health being strongly opposed to new routine 
screening programmes such as CF screening. but at 
the same time bcinp a formally weak Institution with 
access to only few means of enforcement. the issue 01 
authority seems to be an inherent and yet undecided 
part of the ongoing process of the articulation of the 
acceptability of CF screening in Denmark. 
CON(‘l.IISION 
What does the story about the introduction of CF 
screening in Denmark tell us? Did we set a ‘society’ 
deciding upon the acceptance of a new genetic tech- 
nology, or a ‘technology’ forcing itself upon the 
Danish society‘? Neither of both. What WC tried to 
reveal in our story of entrenchment is a process in 
which the development of CF screening in Denmark 
is advanced and shaped by various conditions includ- 
ing. first of all, a strong CF network and an elabor- 
ate regime of prenatal care. and further a high public 
acceptance of abortion and a culture emphasizing 
personal freedom and autonomy. Seen from this 
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perspective, the argument that the matter of CF 
screening is one of ‘when’ not ‘if’, might well apply 
to Denmark too. But it is not simply technology that 
forces itself upon society. At work here is, to use a 
term of the historian technology Thomas Hughes, the 
‘momentum’ of a whole constellation of technology, 
networks and regimes [31]. At the same time, as our 
story shows, such constellations change. When new 
technological options are introduced, we will see the 
articulation of new demands and new issues of ac- 
ceptability. New actors enter the stage, claim auth- 
ority, interfere with networks and attempt to redefine 
regimes. It is in this sense indeed, that the success of 
new technologies depends on negotiations and de- 
cisions in society. Seen from this perspective however, 
we talk about a complex process of socio-technical 
change rather than straightforward political decision- 
making. 
What are the implications of this general con- 
clusion? First of all, in thinking about the question 
how to deal with the implications of human genome 
research, solemn references to our democratic society 
are not enough [32]. What we need are answers to the 
questions: 
(I ) what actors, networks and regimes predeter- 
mine processes of entrenchment of human 
genome technologies in society; and 
(2) how is articulation of demand and accept- 
ability taking place, who is involved and in 
what way’? 
Our sketch of the Danish situation might be com- 
pared, in the light of these questions, to what is going 
on in other countries, as for example the Netherlands, 
in which the issue of CF screening is discussed with 
far more reserve. It would be interesting to see 
whether such differences can be understood in terms 
of differences in networks and regimes, or different 
ways in which articulation of demand and acceptabil- 
ity is taking place*. 
In relation to these empirical and comparative 
questions, we might also raise more normative and 
political issues. What about the role of various 
actorsPresearchers. clinicians. patients and patient 
organizations, public interest groups, regulatory 
agencies, governments----in processes of articulation 
of demand and of acceptability? The case of CF 
screening in Denmark highlights some issues relating 
to this question that have a more general relevance. 
A first point is that articulation of demand for CF 
screening in Denmark has been more in the hands of 
the medical community and its constituency-geneti- 
cists. doctors and patient organization--than in the 
hands of the target population of potential users. Of 
*We intend to proceed with our study according to such a 
comparative approach in Ihc framework of a European 
programme for comparative studies of processes of 
entrenchment and regulation of human genome technol- 
ogies m Europe. See [33]. 
course, we might see the pilot project as a means to 
involve potential users and, as the proponents of 
screening will say, users are free to choose whether 
they accept the offer or not. On this point, indeed, the 
experiences with pilot programmes like that in Den- 
mark are extremely important. What about the 7000 
women that have been screened, how did they decide 
upon the offer that was made to them, how ‘free’ did 
they feel about their decision? A second point is that 
while questions relating to the acceptability of new 
technologies are articulated in studies, debates and 
sometimes controversies, there is often a strong press- 
ure to proceed even in the face of serious uncertainties 
and questions. Two findings from the Danish case are 
significant in this light. First, the reluctance of the 
medical community to make evaluation of acceptabil- 
ity a substantial part of the pilot programme. Second, 
the struggle for authority on these matters. Indeed, 
the question of how to deal with the implications of 
new technologies in society will often become also a 
strongly contested question of how to allocate re- 
sponsibilities and authority to decide what is accept- 
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